Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Posted by on Jun 28th, 2026

Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $9.00.

MGX has been the subject of several analyst reports. Wall Street Zen upgraded Metagenomi from a “strong sell” rating to a “sell” rating in a report on Monday, June 15th. Wells Fargo & Company dropped their target price on Metagenomi from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Weiss Ratings cut Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday.

Read Our Latest Analysis on Metagenomi

Institutional Trading of Metagenomi

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in shares of Metagenomi by 482.9% in the 4th quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock valued at $76,000 after purchasing an additional 17,491 shares during the last quarter. AQR Capital Management LLC acquired a new position in Metagenomi in the first quarter valued at about $119,000. Norges Bank acquired a new position in Metagenomi in the second quarter valued at about $373,000. Marshall Wace LLP acquired a new position in Metagenomi in the second quarter valued at about $222,000. Finally, Jane Street Group LLC acquired a new position in Metagenomi in the second quarter valued at about $235,000.

Metagenomi Stock Performance

Shares of MGX opened at $1.25 on Friday. Metagenomi has a one year low of $1.13 and a one year high of $3.95. The stock has a market capitalization of $47.06 million, a price-to-earnings ratio of -0.54 and a beta of 0.64. The stock has a 50 day moving average price of $1.33 and a 200 day moving average price of $1.48.

Metagenomi (NASDAQ:MGX – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Metagenomi had a negative return on equity of 51.23% and a negative net margin of 384.61%.The firm had revenue of $1.25 million for the quarter, compared to analysts’ expectations of $5.90 million. On average, analysts predict that Metagenomi will post -2.13 earnings per share for the current year.

Metagenomi Company Profile

(Get Free Report)

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

Read More

Analyst Recommendations for Metagenomi (NASDAQ:MGX)

Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.